Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TRQ 1501

Drug Profile

TRQ 1501

Alternative Names: Deep IL 15; Deep IL-15 primed T cells; TRQ-1501

Latest Information Update: 02 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Torque Therapeutics
  • Class Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Immunostimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Lymphoma; Solid tumours

Most Recent Events

  • 08 Nov 2019 Pharmacodynamics data from preclinical trial released by Torque Therapeutics
  • 08 Nov 2019 Torque Therapeutics plans a clinical trial for TRQ 1501 in solid tumours and haematological malignancies (Combination therapy) in latter part of this year and in 2020
  • 18 Jun 2019 Phase-I/II clinical trials in Lymphoma (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (Torque Therapeutics pipeline, June 2019)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top